Introduction
Since its approval in Italy in 1987, rifaximin has been licensed in over 30 countries for the treatment of a variety of gastrointestinal diseases, particularly diarrhea and portal systemic encephalopathy (PSE) ( Table 1) [1]. Rifaximin was approved in the United States in 2004 for the treatment of travelers' diarrhea secondary to noninvasive Escherichia coli [2] . The unique properties of this medication, including its broad spectrum of antimicrobial activity, high fecal concentrations, and low systemic absorption, make this an ideal agent for the treatment of gastrointestinal diseases. In this review, we discuss the published studies that evaluate the effectiveness of rifaximin as a therapeutic agent for different gastrointestinal disorders.
Mechanism of action
Rifaximin is a poorly absorbed bactericidal rifamycin derivative, which inhibits bacterial protein synthesis by irreversibly binding to RpoB, the beta-subunit of the bacterial DNA-dependent RNA polymerase [3] .
Metabolism and pharmacokinetics
The lack of absorption of rifaximin in the gastrointestinal tract enhances fecal concentrations of this drug and limits its systemic toxicity. Studies with radio-labeled rifaximin have demonstrated less than 0.4% of detectable rifaximin in the blood and urine, undetectable levels in the bile and breast milk, and 97% recovered unchanged in the stool after oral ingestion [2, 4] . Fecal concentrations of approximately 8000 mg/g are attained after 3 days of rifaximin 800 mg/day administered to adults suffering travelers' diarrhea [5] .
As a virtually nonabsorbable antibiotic, drug interactions with rifaximin are uncommon. Whereas rifaximin is capable of inducing the cytochrome P450 3A4 (CYP3A4) isoenzyme in in-vitro studies, clinical studies with rifaximin have shown no significant effect on drug metabolism by cytochrome P450 isoenzymes [6, 7] . No dosage adjustments are required for hepatic dysfunction, even with liver failure and hepatic encephalopathy because systemic absorption is minimal [2] .
Antimicrobial activity
Rifaximin is bactericidal against a broad array of enteric pathogens, including gram-positive, gram-negative, aerobic and anaerobic bacteria. An extensive microbiological survey performed by our research group demonstrated that the minimum inhibitory concentration for 90% of microorganism growth (MIC 90 ), ranged from 4 to 64 mg/ml for enteric pathogens isolated over three continents, including enterotoxigenic (ETEC) and enteroaggregative E. coli (EAEC), Salmonella, Shigella, Campylobacter, Plesiomonas, and Aeromonas species [8] . Similar bacterial susceptibility patterns have been confirmed by other studies [9, 10] . With fecal concentrations approaching 8000 mg/g in human hosts, rifaximin easily achieves concentrations effective against these bacterial pathogens [5] .
Rifaximin appears to have some enteric antiprotozoal activity as well. Rifaximin has been shown to provide clinical resolution and intestinal microbiological eradication in a small number of HIV (n ¼ 15) and AIDS (n ¼ 5) patients with Cryptosporidium parvum and Blastocystis hominis gastroenteritis [11, 12] .
Despite high gut concentrations of rifaximin and its broad spectrum of activity, this medication produces minimal alterations in the intestinal microflora. After receiving 2 weeks of rifaximin, patients experienced only a 1 log reduction in intestinal coliforms per gram of stool [13] .
Rifaximin safety profile
With its lack of systemic absorption, rifaximin is a relatively well tolerated medication and is associated with a low incidence of adverse events. More than 1000 patients who received rifaximin as participants in travelers' diarrhea clinical trials reported adverse events at a similar or lower frequency than patients receiving placebo, ciprofloxacin, or TMP-SMX, respectively [13] [14] [15] [16] [17] . No serious adverse events or deaths were reported in these clinical trials. Clinical trials evaluating rifaximin for other gastrointestinal disease further support the safety and tolerability of this medication [18] [19] [20] [21] .
Treatment of travelers' diarrhea
The recommended dosage of rifaximin for the treatment of travelers' diarrhea caused by noninvasive strains of E. coli, including ETEC and EAEC, in patients more than 12 years of age is 200 mg three times per day for 3 days [2, 22] . The effectiveness of rifaximin as a therapeutic agent for travelers' diarrhea has been demonstrated in several pivotal randomized, double-blind clinical trials. The primary endpoint of these trials was the time to last unformed stool (TLUS), defined as the time from the first dose of medication to the passage of the last unformed stool after which patients are declared well. Rifaximin has been shown to be more effective than placebo [15] and similar in efficacy to traditional travelers' diarrhea antibiotics, trimethoprim-sulfamethoxazole (TMP-SMX) [17] and ciprofloxacin [14, 16] , in shortening the duration of travelers' diarrhea.
In a randomized, prospective, double-blind clinical trial including 72 US travelers to Mexico, no significant differences in the TLUS were observed comparing 5-day courses of rifaximin (200, 400, and 600 mg three times per day) and TMP-SMX (160/800 mg twice a day). There was a trend for shorter duration of diarrhea with the administration of rifaximin 200 mg three times a day [17] . 
Prevention of travelers' diarrhea
Some experts consider antibiotic chemoprophylaxis for travelers' diarrhea to be unnecessary and excessive because of their fears of antimicrobial resistance promotion and potential risk of adverse events for a self-limited disease in the majority of travelers' diarrhea cases. However, the recognition of persistent and chronic complications, including postinfectious irritable bowel syndrome (IBS) shown to occur in 5-10% of persons experiencing travelers' diarrhea [23] , has led to a reevaluation of the need for travelers' diarrhea chemoprophylaxis. As a gut-selective antibiotic with minimal systemic toxicity and a lack of drug interactions, rifaximin appears to be an ideal prophylactic drug for travelers' diarrhea [24] .
Two large randomized, double-blind, placebo-controlled clinical trials support the efficacy of rifaximin as a chemoprophylactic agent for travelers' diarrhea. In one doseranging clinical trial with 210 US travelers to Mexico, patients were randomized to either 2 weeks of rifaximin 200 mg once daily (n ¼ 50), 200 mg twice daily (n ¼ 52), 200 mg three times daily (n ¼ 54), or placebo (n ¼ 54). Collectively, 15% of rifaximin patients developed travelers' diarrhea compared to 54% of the placebo group (P ¼ 0.0001). The protection rate against travelers' diarrhea for rifaximin patients was 72% (P < 0.001). All rifaximin doses were superior to placebo for the prevention of travelers' diarrhea [13] .
A second prophylaxis trial with 210 travelers to Mexico compared 2 weeks of rifaximin 600 mg daily dose (n ¼ 106) to placebo (n ¼ 104) for travelers' diarrhea prevention. Rifaximin patients were less likely to develop diarrhea compared to the placebo group (20 vs. 48%, respectively, P < 0.0001) with a travelers' diarrhea protection rate of 58% [25] .
Travelers' diarrhea and invasive enteric pathogens
As a nonabsorbable antibiotic, rifaximin's bactericidal activity appears to be limited to the lumen of the gastrointestinal tract. As a result, rifaximin is less effective in treating invasive bacterial pathogens. In a clinical treatment trial for travelers' diarrhea, rifaximin was less effective than ciprofloxacin in reducing the TLUS and in providing clinical resolution, when the causative agent was an invasive enteric pathogen, such as Shigella species, Campylobacter jejuni, and Salmonella species [16] . In an experimental challenge trial with orally administered Shigella flexneri, rifaximin failed to adequately treat 8 of 13 patients who developed shigellosis. These eight patients required rescue treatment with ciprofloxacin to achieve clinical resolution [26] . Rifaximin is not approved for the treatment of travelers' diarrhea associated with invasive enteric pathogens such as Shigella species, C. jejuni, and Salmonella species and should be avoided when these invasive bacteria are suspected. An alternative antibiotic should be used for travelers' diarrhea patients presenting with fever or dysentery.
In contrast, rifaximin's protective effect against travelers' diarrhea may extend to even travelers' diarrhea cases associated with invasive enteric pathogens. It has been hypothesized that rifaximin may eradicate invasive diarrheagenic pathogens in the gastrointestinal tract prior to mucosal infiltration [27] . In a randomized, double-blind, placebo-controlled prevention trial, 25 healthy adults were experimentally challenged with S. flexneri. Prior to their oral S. flexneri inoculation, patients received either 3 days of rifaximin 200 mg three times a day or placebo. All 15 rifaximin patients were protected and failed to develop diarrhea, whereas 6 of 10 placebo recipients developed shigellosis (P ¼ 0.001) [28] . The effectiveness of rifaximin as a prophylactic agent in southern Asia (Indian subcontinent) should be carried out to determine its value in preventing diarrhea due to invasive enteropathogens.
Portal systemic encephalopathy
Clinical trials have demonstrated that rifaximin is effective for the treatment and prevention of PSE. Rifaximin is believed to reduce ammonia production by eliminating intestinal bacteria involved in the degradation of nitrogenous compounds [29] . In a large randomized, double-blind, placebo-controlled trial (n ¼ 299), rifaximin at a dose of 1100 mg per day reduced the risk of developing breakthrough PSE by 58% and the risk of PSErelated hospitalizations by 48% compared to placebo in cirrhotic patients with a previous history of PSE [30] .
Rifaximin was compared to neomycin in a small randomized, double-blind, clinical trial (n ¼ 30). Similar efficacy in clinical resolution of the encephalopathy was shown between the two antibiotics, but rifaximin led to an earlier reduction in serum ammonia levels compared to neomycin [31] . Rifaximin has been shown to be as or more effective in treating PSE as the nonabsorbable disaccharides, lactulose [32, 33] and lactitol [21] . Decreased hospitalizations and length of hospital stays have been associated with rifaximin compared to lactulose [20] . Better tolerability is one of the key advantages of rifaximin compared to these other PSE therapies. With its minimal systemic absorption, rifaximin is associated with few adverse events. Neomycin use may be complicated by nephrotoxicity and ototoxicity [32] . The disaccharides can cause significant diarrhea and gastrointestinal complaints such as flatulence, dyspepsia, anorexia [33] . Rifaximin has been designated as an 'orphan drug' for the treatment of PSE by the FDA.
Clostridium difficile infection
Rifaximin has excellent in-vitro activity for Clostridium difficile [34] [35] [36] . The minimum inhibitory concentration (MIC 90 ¼ 0.015 mg/ml) was lower for rifaximin than for vancomycin, metronidazole, and other antibiotics active against C. difficile in one study [36] . Clinical studies evaluating rifaximin treatment of C. difficile infection (CDI) are limited to case reports and one small clinical trial (n ¼ 20), in which 9 of 10 CDI patients responded to rifaximin compared to 10 of 10 patients receiving vancomycin. However, clinical resolution of CDI occurred more rapidly with vancomycin than rifaximin [37] . Two case series described rifaximin use for recurrent CDI [38, 39] . Rifaximin was highly effective for both prevention and treatment of recurrent CDI with response rates of 88 [38] and 83% [39] , respectively. One case report also described extended co-administration (7 weeks) of rifaximin with oral vancomycin and a probiotic for the successful treatment of refractory CDI [40] . Larger prospective clinical trials are needed to confirm the efficacy of rifaximin for treatment of primary and recurrent CDI.
The development of C. difficile resistance to rifaximin during therapy needs to be monitored. Evidence for C. difficile resistance is primarily based on in-vitro susceptibility testing for rifampin. Although agar dilution testing for C. difficile antibiotic susceptibility is considered as the most accurate test, most laboratories are not capable of performing this labor-intensive assay and rely on the episolometer test (E-test) to screen for antibiotic susceptibility. An E-test strip is currently not available for rifaximin. As a result, antibiotic susceptibility testing with the E-test rifampin strips has been used as a surrogate assay, since both antibiotics belong to the rifamycin class [41 ] . Significant rifampin resistance has been demonstrated among C. difficile isolates, particularly among epidemic BI/NAP1 C. difficile strains [41 ,42] . In one institution, approximately 81% of C. difficile isolates were found to be resistant to rifampin [42] . Resistance to rifampin may be related to mutations in the rpoB gene, which encodes for the b-subunit of C. difficile RNA polymerase [41 ] . In a preliminary study, we have shown that significant discordance between the susceptibility profiles of the two antibiotics for C. difficile may exist when the agar dilution method is used [34] . Further evaluation of C. difficile susceptibility to rifaximin and the correlation between rifampin and rifaximin resistance is needed. It is also unknown whether these resistance mutations correlate with clinical failures.
Small intestinal bowel overgrowth and irritable bowel syndrome
Small bowel bacterial overgrowth (SIBO) may be associated with a variety of bacteria, both aerobic and anaerobic microbes [43] . As a result, an antimicrobial like rifaximin, with a broad spectrum of activity resulting in high luminal levels of drug, is ideal for the treatment of SIBO. Studies evaluating rifaximin as a treatment for SIBO are limited and involve a range of dosages. A clinical response of 59% in SIBO patients was shown in a small clinical trial (n ¼ 33), suggesting a potential role for rifaximin as a treatment for SIBO [44] . Microbiological decontamination responses to rifaximin therapy, measured by hydrogen breath tests, range from 59 [44] to 70.4% [45, 46] . However, SIBO may recur in up to 44% of patients, successfully treated with a 1 week course of rifaximin (1200 mg per day), particularly in those patients with predisposing conditions for SIBO, such as chronic proton-pump inhibitor use [47] . Retreatment with rifaximin may be effective for these recurrences and for those recurrences failing to respond to other antibiotics [48] .
Higher doses of rifaximin may be more effective for eradicating SIBO. Rifaximin 1200 mg per day led to 70% normalization of glucose breath tests compared to 27% with chlortetracycline 1 g per day for SIBO patients [46] . Higher doses of rifaximin (1600 vs. 1200 mg per day) were more effective in normalizing breath tests (80 vs. 58%, respectively) in another study [49] . More accurate methods of detecting bacterial overgrowth than breath tests, which are influenced by gut transit, are needed.
Although the underlying pathogenesis of IBS is not well understood and the diagnosis is established by Rome II clinical criteria [50] , it is hypothesized that SIBO contributes to this gastrointestinal disease. The clinical syndromes of IBS and SIBO overlap, and between 40 and 80% of IBS patients have abnormal hydrogen breath tests [51] [52] [53] or increased small bowel bacterial counts [54] . In addition, clinical improvement of IBS symptoms appears to be associated with normalization of hydrogen breath tests following antibiotic treatment [53] .
Symptomatic improvement in IBS symptoms has been demonstrated with tetracyclines and fluoroquinolones, with high relapse rates following antibiotic discontinuation [55] . There are concerns about the development of antibiotic resistance with the widespread use of antimicrobial agents. Two randomized, double-blind, placebocontrolled trials evaluated the efficacy of rifaximin treatment for IBS. In the first trial, 87 patients diagnosed with IBS by Rome I criteria received either rifaximin 400 mg or placebo three times per day for 10 days. Throughout 10 weeks of follow-up, rifaximin patients experienced greater symptomatic improvement than the placebo group [18] . In the second trial, 70 patients with IBS diagnosed by Rome II criteria were randomized to either 10 days of rifaximin 400 mg or placebo twice a day. Rifaximin patients experienced significantly greater symptomatic relief than the placebo group. Interestingly, none of these IBS patients had an abnormal baseline hydrogen breath test [56] .
Inflammatory bowel disease and pouchitis
An abnormal host immune response associated with a loss of tolerance to the commensal intestinal microbiome is believed to play an important role in the pathogenesis of inflammatory bowel diseases (IBDs), including Crohn's disease, ulcerative colitis, and pouchitis [57] . As a result, antibiotics such as metronidazole and ciprofloxacin have been used for the medical management of IBD, including refractory Crohn's disease [58] . However, despite the potential beneficial effect of prolonged antimicrobial therapy in IBD, side effects of these antibiotics including peripheral neuropathy with metronidazole and tendinitis or tendon rupture with ciprofloxacin and concern for antibiotic resistance limit their extended use. As a nonabsorable antibiotic, rifaximin is an attractive alternative.
Crohn's disease
Rifaximin appears promising as treatment for IBD, but a lack of well designed clinical trials with sufficient power contribute to the difficulty in assessing the efficacy of rifaximin for IBD. The optimal rifaximin dose also remains to be determined. In one multicenter, randomized, double-blind, placebo-controlled clinical trial, less treatment failures were seen with rifaximin (n ¼ 83), but there were no significant differences in clinical remission or improvement in active Crohn's disease patients receiving rifaximin compared to placebo [19] .
A small (n ¼ 29) open-label study of prolonged rifaximin therapy (200 mg three times per day for 16 weeks) demonstrated clinical improvement of active Crohn's disease [59] . Rifaximin 800 mg per day was effective as first-line therapy for small intestinal Crohn's disease, with symptomatic and endoscopic healing, in a small case series of three patients [60] .
Ulcerative colitis
Rifaximin may serve as a steroid-sparing treatment agent for some cases of ulcerative colitis. In one open-label study of 30 patients receiving maintenance mesalamine, rifaximin was used instead of steroids because these patients were poor candidates of steroid therapy due to their underlying conditions. Approximately 77% of these ulcerative colitis patients experienced clinical resolution with rifaximin 400 mg twice daily for 4 weeks [61] . In another trial, no significant clinical improvement with rifaximin compared to placebo was shown for patients with moderate-to-severe ulcerative colitis refractory to steroid therapy [62] .
Pouchitis
Pouchitis is the most common complication of ileal pouch-anal anastomosis following restorative proctocolectomy, which is a surgical procedure performed for ulcerative colitis and familial adenomatous polyposis coli (FAP). Inflammation of the ileal pouch occurs in up to 50% of ulcerative colitis patients following this procedure [63, 64] . It has been suggested that pouchitis may be related to fecal stasis with increased proliferation of anaerobic intestinal flora [65] . Antibiotics such as metronidazole, ciprofloxacin, or a combination of these two are frequently empirically administered to treat pouchitis [66] . The majority of patients respond to these antibiotics but 1-9% of pouchitis cases will be chronic and refractory to traditional antibiotics and other treatment modalities [67] . Rifaximin as monotherapy (400 mg TID for 4 weeks) for active acute and chronic pouchitis in a small randomized, double-blind, placebo-controlled trial failed to show any significant benefit compared to placebo [68] . However, the combination of rifaximin 1 g twice daily and ciprofloxacin 500 mg twice daily for 2 weeks was shown to be effective in providing clinical improvement or remission in up to 88% of chronic refractory pouchitis cases in several small open-label trials [69, 70] . Rifaximin may also be effective as chronic maintenance therapy for chronic pouchitis patients, who require continuous or pulse-dosed antibiotic therapy to avoid relapsing. Among 51 patients with antibiotic-dependent pouchitis, 33 (65%) were successfully maintained on rifaximin suppressive therapy for at least 3 months in an open-label study [71] .
Colonic diverticular disease
Although the majority of individuals with diverticular disease are asymptomatic, approximately 20% of patients experience clinical illness and are at risk for complications such as diverticulitis and hemorrhage [72] . Dietary fiber supplementation is considered the standard therapy for symptomatic diverticular disease and may prevent complications [73] . Multiple randomized clinical studies involving over 1500 patients have demonstrated that the addition of monthly rifaximin to fiber supplementation may further improve symptoms and prevent complications in patients with symptomatic, uncomplicated diverticular disease [74] [75] [76] [77] .
Conclusion
Rifaximin is a broad-spectrum nonabsorbed rifamycin antibiotic with an excellent safety profile, a lack of drug interactions, and minimal effect on the intestinal microbiome. This gut-selective antimicrobial is currently approved for the treatment of travelers' diarrhea caused with noninvasive E. coli strains. Rifaximin appears promising as a therapeutic and preventive agent for other gastrointestinal diseases as well. Published large, well designed, controlled clinical trials best support the use of rifaximin for two additional gastrointestinal indications: prevention of travelers' diarrhea and treatment of PSE. Although there is a potential for rifaximin to be effective for other gastrointestinal diseases including small intestinal bowel overgrowth, IBS, C. difficile infection, IBDs, and diverticular disease, more studies are needed to confirm the beneficial role of rifaximin in these diseases.
